DCRI and SAS Open Data to Researchers
A collaboration between The Duke Clinical Research Institute (DCRI) analytics, business intelligence and data management software and services provider SAS will give researchers access, analytics and data management tools to its database that includes 45 years of cardiovascular patient data collected by the Duke University Health System, including de-identified records for patients; data from more than 100,000 procedures; treatment histories, and more. The information can be used to test clinical hypotheses, develop clinical trial protocols and help researchers assess long-term outcomes and assess time trends. The DCRI and SAS are constructing a data governance plan to ensure the reliability of the data sets and to process requests as efficiently as possible. Researchers can apply for access to the data sets at soar.dcri.org. Read the full release here
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
